FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?
Moderna (NASDAQ: MRNA) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer. In fact, its cancer vaccine is in late-stage development and has generated positive clinical data.Still, investors haven't yet jumped on board in great numbers as can be seen in the share performance -- the stock has plummeted 74% over the past year. Recently, major shifts at the U.S. Food and Drug Administration (FDA), the agency overseeing the review of potential new drugs, hasn't helped matters. Just days ago, Peter Marks, a key vaccine official at the agency, resigned, sending Moderna shares lower once again.Is Moderna stock now one to avoid or a bad-news buy?Continue reading
Moderna (NASDAQ: MRNA) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer. In fact, its cancer vaccine is in late-stage development and has generated positive clinical data.
Still, investors haven't yet jumped on board in great numbers as can be seen in the share performance -- the stock has plummeted 74% over the past year. Recently, major shifts at the U.S. Food and Drug Administration (FDA), the agency overseeing the review of potential new drugs, hasn't helped matters. Just days ago, Peter Marks, a key vaccine official at the agency, resigned, sending Moderna shares lower once again.
Is Moderna stock now one to avoid or a bad-news buy?
